The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. - Archive ouverte HAL Access content directly
Journal Articles Cell Host and Microbe Year : 2010

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

(1) , (2) , (3) , (1) , (1) , (3) , (4) , (5) , (6) , (7) , (5) , , (8) , (4) , (2) , (1) , (1)
1
2
3
4
5
6
7
8

Abstract

Antibodies protect against homologous Dengue virus (DENV) infection but can precipitate severe dengue by promoting heterotypic virus entry via Fcγ receptors (FcγR). We immortalized memory B cells from individuals after primary or secondary infection and analyzed anti-DENV monoclonal antibodies (mAbs) thus generated. MAbs to envelope (E) protein domain III (DIII) were either serotype specific or cross-reactive and potently neutralized DENV infection. DI/DII- or viral membrane protein prM-reactive mAbs neutralized poorly and showed broad cross-reactivity with the four DENV serotypes. All mAbs enhanced infection at subneutralizing concentrations. Three mAbs targeting distinct epitopes on the four DENV serotypes and engineered to prevent FcγR binding did not enhance infection and neutralized DENV in vitro and in vivo as postexposure therapy in a mouse model of lethal DENV infection. Our findings reveal an unexpected degree of cross-reactivity in human antibodies against DENV and illustrate the potential for an antibody-based therapy to control severe dengue.

Dates and versions

pasteur-00530282 , version 1 (28-10-2010)

Identifiers

Cite

Martina Beltramello, Katherine L. Williams, Cameron P. Simmons, Annalisa Macagno, Luca Simonelli, et al.. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.. Cell Host and Microbe, 2010, 8 (3), pp.271-83. ⟨10.1016/j.chom.2010.08.007⟩. ⟨pasteur-00530282⟩

Collections

PASTEUR CNRS
206 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More